Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 34.5% in August

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totaling 43,251 shares, a drop of 34.5% from the August 15th total of 66,082 shares. Approximately 3.3% of the shares of the company are sold short. Based on an average daily volume of 23,843 shares, the short-interest ratio is presently 1.8 days.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Aspire Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Aspire Biopharma Price Performance

Aspire Biopharma stock opened at $8.58 on Thursday. The firm has a 50 day simple moving average of $7.63 and a 200-day simple moving average of $12.73. The stock has a market capitalization of $12.01 million, a PE ratio of -0.12 and a beta of 0.17. Aspire Biopharma has a 12-month low of $3.31 and a 12-month high of $562.92.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.